NCBIO Blog
NC treasurer: NC hospitals use 340B to profit a patient’s expense
NC treasurer: NC hospitals use 340B to profit a patient’s expense A new report from the North Carolina State Treasurer found North Carolina hospitals use the federal 340B program to profit at the expense of patients, teachers and state employees. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to…
Read MoreStartups struggle with new R&D tax rule
Startups struggle with new R&D tax rule A 2022 tax rule requiring the amortization of research and development expenses has created significant challenges for many life sciences startups and small businesses. Previously, grant money received by these companies and spent on R&D could be deducted immediately in full, but the new rule forces them to…
Read MoreAMR is a silent killer that threatens our health in North Carolina and beyond
AMR is a silent killer that threatens our health in North Carolina and beyond The small red bump on my son’s hand looked at first like a bug bite. But when the hand swelled to the point of immobility and we took him to the doctor, the diagnosis was MRSA, an infection from a type…
Read MoreStudy projects extensive damage to drug development, jobs from drug-pricing policies
A new study estimates that there would be 237 fewer FDA approvals of new medicines over the next decade and 1.1 million lost jobs if proposals to expand government-mandated drug pricing policies are implemented.
Read MoreCollaboration and statewide support make North Carolina a thriving hub of urgently needed innovation in rare disease.
The rarest day on the calendar is the one that does not even occur in every year: February 29. In 2008, this was designated as Rare Disease Day and since then, the last day of February has been an opportunity to draw attention to, honor and support people living with these conditions.
Read MoreWhere things stand with the TRIPS waiver
The World Trade Organization is considering continuing to waive certain intellectual property rights on COVID-19 diagnostics and therapeutics, following a recent decision to do the same for vaccines.
Read MoreExpanding COVID IP waiver would harm small, medium enterprises, CSBA says
Every member of the Council of State Bioscience Associations signed a letter to President Joe Biden expressing serious concerns with the proposed expansion of IP protections for COVID technology.
Read MorePart D drug price “negotiation” comes at cost of jobs, investment, cures
Congress passed the Inflation Reduction Act on Aug. 12. Included in the law is a provision that gives Medicare Part D the ability to “negotiate” the price of medicines for the first time. Negotiate is in quotation marks because lawmakers are being ironic; no one can legitimately call the new price-setting policy a negotiation.
Read MoreBIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy
BIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy On April 7, the Centers for Medicare and Medicaid Services held to its original decision to limit coverage of the Biogen’s Alzheimer’s disease treatment Aduhelm — along with other drugs like it — to clinical trials. Michelle McMurry-Heath, M.D., Ph.D., president and…
Read MoreBiotech joins efforts to aid in humanitarian relief in Ukraine
Biotech joins efforts to aid in humanitarian relief in Ukraine The biotech and life sciences industry is coming together to donate a range of critical medical supplies, equipment, and medications to the people of Ukraine. “The conflict in Ukraine and violence from Russia defies international law, norms and modern sensibilities,” said BIO President and CEO…
Read More